LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference�
Go back to LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference�| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 218.03 +0.88 (0.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $217.15 | 52 Week High | $333.65 | |||
| Open | $221.00 | 52 Week Low | $223.02 | |||
| Day High | $222.25 | P/E | 27.92 | |||
| Day Low | $215.56 | EPS | $7.81 | |||
| Volume | 167,381 | |||||
